The acquisition adds a first-in-class myeloid cell engager for deep B-cell depletion to Sanofi’s expanding autoimmune arsenal.

March 20, 2025 — Paris – Global biopharmaceutical giant Sanofi has announced its acquisition of DR-0201, a promising bispecific antibody developed by California-based biotech Dren Bio, in a deal valued at $600 million upfront and up to $1.9 billion in total. This acquisition positions Sanofi at the forefront of next-generation treatments for autoimmune diseases, with the potential to reset the immune system in patients with refractory conditions such as lupus.

What is DR-0201?

DR-0201 is a CD20-directed bispecific myeloid cell engager (MCE) designed to induce deep B-cell depletion through targeted phagocytosis. Unlike traditional B-cell therapies, which may struggle with incomplete depletion or treatment resistance, DR-0201 engages tissue-resident and circulating myeloid cells to eliminate pathogenic B cells at their root.

Currently in Phase 1 clinical trials, DR-0201 has shown encouraging results in both preclinical and early clinical settings—demonstrating robust, durable B-cell clearance. This mode of action holds potential not only for more effective symptom control but also for inducing treatment-free remission in autoimmune conditions.

A Strategic Leap in Immunology

Sanofi’s R&D chief Dr. Houman Ashrafian called DR-0201 “at the frontier of treating autoimmune diseases,” emphasizing its role in delivering breakthrough medicines where unmet medical needs persist.

“Through our own research and strategic licensing and acquisitions, we continue to advance our goal of becoming the leader in immunology,” said Ashrafian.

The acquisition reflects Sanofi’s continued pivot toward high-impact, immune-modulating therapies, a space that has seen explosive growth driven by biologics and precision immunotherapies.

Deal Details

Under the terms of the agreement:

• Sanofi will acquire DR-0201 via a dedicated affiliate, Dren-0201, for $600 million upfront
• Additional milestone payments could total $1.3 billion, linked to clinical and commercial achievements
• Dren Bio will retain its independence and continue advancing its broader pipeline of antibody therapeutics

The transaction is expected to close in Q2 2025, pending regulatory approvals.

The Bigger Picture: Immune Reset as a New Therapeutic Paradigm

Autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, affect millions globally and often require lifelong treatment. Traditional therapies—while effective for some—fall short in achieving long-term remission.

The emerging approach of deep immune resetting via B-cell depletion and myeloid cell engagement represents a promising new frontier. If successful, therapies like DR-0201 could help patients achieve durable remission and reduce dependence on chronic immunosuppressive drugs.

For Dren Bio, this is a significant validation of its targeted myeloid engager and phagocytosis platform—a bispecific antibody technology designed to selectively activate innate immune responses against disease-driving cells.

“Sanofi is ideally positioned to unlock the power of immune reset for autoimmune patients with this novel myeloid cell engager,” said Dr. Nenad Tomasevic, Co-founder and CEO of Dren Bio.